Shares of Alembic Pharmaceuticals are likely to gain focus on Monday after the drugmaker received renewed approval from the US Food and Drug Administration (USFDA) for a broadly prescribed cardiovascular therapy.

Alembic Pharmaceuticals informed the exchanges that it has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Tablets USP in 30 mg, 60 mg, 90 mg and 120 mg strengths. The company announced the approval on Saturday, November 15.

Major approval for cardiovascular therapy

A drug used to treat high blood pressure and angina, Bausch Health US, LLC’s reference listed drug is therapeutically equivalent to Cardizem Tablets. The tablets are indicated for the management of chronic stable angina and angina caused by coronary artery spasm.

With this approval, Alembic now has a total of 230 ANDA approvals from the USFDA, including 210 final approvals and 20 provisional approvals.

Shares of Alembic Pharmaceuticals fell 1.28% on Friday to Rs. was settled at 904.20. The stock is down 14% so far in 2025.

Also Read | Tata Motors CV hits top gear on debut post demerger. Here are 7 takeaways from the list

(disclaimer: Recommendations, suggestions, opinions and views given by experts are their own. (These do not represent the views of The Economic Times)